Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Keyphrases

• 18 Years Old 8%
• 95% Confidence Interval 8%
• Adult Patients 100%
• Adverse Events 8%
• Bone Sarcoma 8%
• Clinical Management 8%
• Clinical Trials 8%
• Durable Response 16%
• Extended Survival 8%
• First-in-class 8%
• Fusion Protein 25%
• Fusion Sarcoma 100%
• Gastrointestinal Stromal Tumor 8%
• Highly Selective 8%
• Kinase Fusion 100%
• Larotrectinib 100%
• Line of Therapy 8%
• Long Follow-up 8%
• Modified Response Evaluation Criteria in Solid Tumors (mRECIST) 8%
• NTRK Fusion 33%
• Objective Response Rate 8%
• Pediatric Patients 8%
• Robust Response 8%
• Safety Profile 8%
• Sarcoma 25%
• Soft Tissue Sarcoma 8%
• Solid Tumors 8%
• Subset Analysis 8%
• Survival Benefit 8%
• Treatment Discontinuation 8%
• Treatment Emergent 25%
• Treatment-related Adverse Events 8%
• Tropomyosin Receptor Kinase B 100%
• Tropomyosin Receptor Kinase Inhibitor 8%
• Tumor Subtype 8%
• Twice Daily 8%

Medicine and Dentistry

• Adverse Event 16%
• Chimeric Protein 25%
• Clinical Management 8%
• Clinical Trial 8%
• Connective Tissue Cancer 100%
• Gastrointestinal Stromal Tumor 8%
• Gene Fusion 25%
• Larotrectinib 100%
• Malignant Neoplasm 16%
• Neoplasm 8%
• Osteosarcoma 8%
• Pediatrics Patient 8%
• Phosphotransferase 100%
• Phosphotransferase Inhibitor 8%
• Receptor 100%
• Side Effect 8%
• Soft Tissue Sarcoma 8%
• Solid Malignant Neoplasm 8%
• Tropomyosin 100%